SURGERY FOLLOWED BY CHEMORADIOTHERAPY + C225 FOR HEAD AND NECK CARCINOMA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 (from ClinicalTrials.gov请参阅 本研究不再招募患者。 基本原理：单克隆抗体如西妥昔单抗可以定位肿瘤细胞，并杀死它们或向它们递送肿瘤杀伤物质而不伤害正常细胞。化疗中使用的药物，如顺铂和多西他赛，以不同的方式阻止肿瘤细胞分裂，使它们停止生长或死亡。放射治疗使用高能x射线来破坏肿瘤细胞。顺铂和多西他赛可能使肿瘤细胞对放射治疗更敏感。将单克隆抗体与放化疗结合并在手术后给予它们可以杀死任何残留的肿瘤细胞。 目得：这项随机II期试验正在研究辅助西妥昔单抗联合顺铂放化疗，以观察其与辅助西妥昔单抗联合多西他赛放化疗在治疗切除的III期或IV期鳞状细胞癌（癌症）或头颈部淋巴上皮瘤患者中的效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov) This study is no longer recruiting patients. RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Cisplatin and docetaxel may make the tumor cells more sensitive to radiation therapy. Combining a monoclonal antibody with chemoradiotherapy and giving them after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase II trial is studying adjuvant cetuximab given together with chemoradiotherapy using cisplatin to see how well it works compared to adjuvant cetuximab given together with chemoradiotherapy using docetaxel in treating patients with resected stage III or stage IV squamous cell carcinoma (cancer) or lymphoepithelioma of the head and neck.